SOLID TUMORS HARBORING NTRK FUSION
Clinical trials for SOLID TUMORS HARBORING NTRK FUSION explained in plain language.
Never miss a new study
Get alerted when new SOLID TUMORS HARBORING NTRK FUSION trials appear
Sign up with your email to follow new studies for SOLID TUMORS HARBORING NTRK FUSION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill targets rare gene in Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called larotrectinib in 75 adults with advanced solid tumors that have a specific gene change (NTRK fusion). The main goal was to check the drug's safety and find the right dose. Participants had cancers that stopped responding to other treatments or …
Matched conditions: SOLID TUMORS HARBORING NTRK FUSION
Phase: PHASE1 • Sponsor: Bayer • Aim: Disease control
Last updated May 17, 2026 08:12 UTC
-
New drug shrinks tumors in rare Gene-Driven cancers
Disease control CompletedThis study tested the drug larotrectinib in 215 adults with various solid cancers that have a specific change in the NTRK gene. The drug works by blocking the faulty gene's signals that make cancer grow. The main goal was to see how many patients had their tumors shrink or disapp…
Matched conditions: SOLID TUMORS HARBORING NTRK FUSION
Phase: PHASE2 • Sponsor: Bayer • Aim: Disease control
Last updated May 15, 2026 11:56 UTC